283 related articles for article (PubMed ID: 28993169)
1. Anti-tuberculosis drug combination for controlled oral delivery using 3D printed compartmental dosage forms: From drug product design to in vivo testing.
Genina N; Boetker JP; Colombo S; Harmankaya N; Rantanen J; Bohr A
J Control Release; 2017 Dec; 268():40-48. PubMed ID: 28993169
[TBL] [Abstract][Full Text] [Related]
2. 3D-Printed Isoniazid Tablets for the Treatment and Prevention of Tuberculosis-Personalized Dosing and Drug Release.
Öblom H; Zhang J; Pimparade M; Speer I; Preis M; Repka M; Sandler N
AAPS PharmSciTech; 2019 Jan; 20(2):52. PubMed ID: 30617660
[TBL] [Abstract][Full Text] [Related]
3. Ascorbic acid improves stability and pharmacokinetics of rifampicin in the presence of isoniazid.
Rajaram S; Vemuri VD; Natham R
J Pharm Biomed Anal; 2014 Nov; 100():103-108. PubMed ID: 25151231
[TBL] [Abstract][Full Text] [Related]
4. A mesoporous silicon/poly-(DL-lactic-co-glycolic) acid microsphere for long time anti-tuberculosis drug delivery.
Xu W; Wei X; Wei K; Cao X; Zhong S
Int J Pharm; 2014 Dec; 476(1-2):116-23. PubMed ID: 25271077
[TBL] [Abstract][Full Text] [Related]
5. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
[TBL] [Abstract][Full Text] [Related]
6. Controlled Release of 5-Fluorouracil from Alginate Beads Encapsulated in 3D Printed pH-Responsive Solid Dosage Forms.
Gioumouxouzis CI; Chatzitaki AT; Karavasili C; Katsamenis OL; Tzetzis D; Mystiridou E; Bouropoulos N; Fatouros DG
AAPS PharmSciTech; 2018 Nov; 19(8):3362-3375. PubMed ID: 29948989
[TBL] [Abstract][Full Text] [Related]
7. Oral matrix tablet formulations for concomitant controlled release of anti-tubercular drugs: design and in vitro evaluations.
Hiremath PS; Saha RN
Int J Pharm; 2008 Oct; 362(1-2):118-25. PubMed ID: 18640251
[TBL] [Abstract][Full Text] [Related]
8. 3D-Printed Network Structures as Controlled-Release Drug Delivery Systems: Dose Adjustment, API Release Analysis and Prediction.
Korte C; Quodbach J
AAPS PharmSciTech; 2018 Nov; 19(8):3333-3342. PubMed ID: 29855799
[TBL] [Abstract][Full Text] [Related]
9. Spray-dried particles as pulmonary delivery system of anti-tubercular drugs: design, optimization, in vitro and in vivo evaluation.
Garg T; Goyal AK; Rath G; Murthy RS
Pharm Dev Technol; 2016 Dec; 21(8):951-960. PubMed ID: 26334961
[TBL] [Abstract][Full Text] [Related]
10. Fabrication of an osmotic 3D printed solid dosage form for controlled release of active pharmaceutical ingredients.
Gioumouxouzis CI; Tzimtzimis E; Katsamenis OL; Dourou A; Markopoulou C; Bouropoulos N; Tzetzis D; Fatouros DG
Eur J Pharm Sci; 2020 Feb; 143():105176. PubMed ID: 31809907
[TBL] [Abstract][Full Text] [Related]
11. Pharmaceutical formulation of a fixed-dose anti-tuberculosis combination.
Danckwerts MP; Ebrahim S; Pillay V
Int J Tuberc Lung Dis; 2003 Mar; 7(3):289-97. PubMed ID: 12661846
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of highly branched cyclic dextrin in inhalable particles of combined antibiotics for the pulmonary delivery of anti-tuberculosis drugs.
Kadota K; Senda A; Tagishi H; Ayorinde JO; Tozuka Y
Int J Pharm; 2017 Jan; 517(1-2):8-18. PubMed ID: 27913241
[TBL] [Abstract][Full Text] [Related]
13. A thermo-responsive and self-healing liposome-in-hydrogel system as an antitubercular drug carrier for localized bone tuberculosis therapy.
Liu P; Guo B; Wang S; Ding J; Zhou W
Int J Pharm; 2019 Mar; 558():101-109. PubMed ID: 30634030
[TBL] [Abstract][Full Text] [Related]
14. A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products.
Singh S; Mohan B
Int J Tuberc Lung Dis; 2003 Mar; 7(3):298-303. PubMed ID: 12661847
[TBL] [Abstract][Full Text] [Related]
15. Comparative bioavailability of rifampicin and isoniazid in fixed-dose combinations and single-drug formulations.
Hao LH; Guo SC; Liu CC; Zhu H; Wang B; Fu L; Chen MT; Zhou L; Chi JY; Yang W; Nie WJ; Lu Y
Int J Tuberc Lung Dis; 2014 Dec; 18(12):1505-12. PubMed ID: 25517820
[TBL] [Abstract][Full Text] [Related]
16. In vivo/in vitro pharmacokinetic and pharmacodynamic study of spray-dried poly-(dl-lactic-co-glycolic) acid nanoparticles encapsulating rifampicin and isoniazid.
Booysen LL; Kalombo L; Brooks E; Hansen R; Gilliland J; Gruppo V; Lungenhofer P; Semete-Makokotlela B; Swai HS; Kotze AF; Lenaerts A; du Plessis LH
Int J Pharm; 2013 Feb; 444(1-2):10-7. PubMed ID: 23357255
[TBL] [Abstract][Full Text] [Related]
17. Formulation and statistical optimization of a novel crosslinked polymeric anti-tuberculosis drug delivery system.
du Toit LC; Pillay V; Danckwerts MP; Penny C
J Pharm Sci; 2008 Jun; 97(6):2176-207. PubMed ID: 17879985
[TBL] [Abstract][Full Text] [Related]
18. 3D printed bilayer tablet with dual controlled drug release for tuberculosis treatment.
Ghanizadeh Tabriz A; Nandi U; Hurt AP; Hui HW; Karki S; Gong Y; Kumar S; Douroumis D
Int J Pharm; 2021 Jan; 593():120147. PubMed ID: 33278493
[TBL] [Abstract][Full Text] [Related]
19. 3D printed capsules for quantitative regional absorption studies in the GI tract.
Smith D; Kapoor Y; Hermans A; Nofsinger R; Kesisoglou F; Gustafson TP; Procopio A
Int J Pharm; 2018 Oct; 550(1-2):418-428. PubMed ID: 30172750
[TBL] [Abstract][Full Text] [Related]
20. Oral solid lipid nanoparticle-based antitubercular chemotherapy.
Pandey R; Sharma S; Khuller GK
Tuberculosis (Edinb); 2005; 85(5-6):415-20. PubMed ID: 16256437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
